Garry Neil, M.D.

Dr. Neil joined Aevi Genomic Medicine formerly Medgenics in September 2013 as Chief Scientific Officer.  He has held several senior positions in biopharmaceutical and R&D at Astra Merck, AstraZeneca, EMD Pharmaceuticals and was a Partner at Apple Tree Partners, a life sciences private equity fund.  Prior to joining Apple Tree Partners in 2012, he was Corporate VP of Science & Technology at Johnson & Johnson, and Group President. Under his leadership, a number of important new medicines for the treatment of cancer, infectious disease, metabolic diseases, women’s health, central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal diseases gained initial or expanded approvals.

Dr. Neil holds an M.D. from the University Of Saskatchewan College Of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. Dr. Neil completed his postdoctoral research fellowship at the Research Institute of Scripps Clinic and had faculty positions at the Ludwig Institute for Cancer Research, the University of Iowa and the University of Pennsylvania (adjunct).

Dr. Neil serves on the boards of GTX Inc. and Arena Pharmaceuticals. He was a past member of the Science Management Review Board of the NIH, Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA), Science and Regulatory Executive Committee and the PhRMA Foundation Board and the founding Chairman of Transcelerate Biopharmaceuticals, Inc. and Foundation for the US National Institute of Health.

Dr. Neil, a founding board member, joined the Reagan-Udall Foundation for the FDA Board of Directors in 2008.